ImmunityBio
Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune SystemCareers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
About Us
ImmunityBio, is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptide, fusion protein, cytokine, monoclonal antibody, adenovirus and yeast vaccine therapies.
Recent News
Dr. Soon-Shiong to Launch ImmunityBio, an Immunotherapy Company at Upcoming Jefferies 2019 Annual Healthcare Conference
Contact Us
© 2019 ImmunityBio, Inc. All rights reserved.